$0.95
0.00 (-0.16%)
Open$0.96
Previous Close$0.95
Day High$1.00
Day Low$0.92
52W High$2.95
52W Low$0.77
Volume—
Avg Volume68.7K
Market Cap4.97M
P/E Ratio—
EPS$-4.58
SectorBiotechnology
Analyst Ratings
Strong Sell
8 analysts
Price Target
+2,123.5% upside
Current
$0.95
$0.95
Target
$21.09
$21.09
$14.27
$21.09 avg
$34.90
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.26M | 557.3K | 516.3K |
| Net Income | -195,536,502 | 76.7K | 85.4K |
| Profit Margin | -1,132.4% | 13.8% | 16.5% |
| EBITDA | -144,481,522 | 122.1K | 108.8K |
| Free Cash Flow | — | 55.8K | 59.0K |
| Rev Growth | +166.9% | +2.4% | +15.9% |
| Debt/Equity | 0.21 | 0.52 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |